1-2 of 2
Danny Himsel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Andreas Hochhaus, Andreas Burchert, Susanne Saussele, Gabriela M Baerlocher, Jiří Mayer, Tim H. Brümmendorf, Paul La Rosée, Dominik Heim, Stefan W. Krause, Philipp le Coutre, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hanel, Frank Stegelmann, Georg-Nikolaus Franke, Markus P. Radsak, Volker Kunzmann, Daniela Zackova, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Christian Fabisch, Thomas Ernst, Markus Pfirrmann
Journal: Blood
Blood (2023) 142 (Supplement 1): 446.
https://doi.org/10.1182/blood-2023-182792
Published: 2023
Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Andreas Hochhaus, MD, Andreas Burchert, MD, Susanne Saussele, MD, Gabriela M Baerlocher, MD, Tim H Brümmendorf, MD, Paul La Rosée, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp D le Coutre, MD, Dietger Niederwieser, MD, Thoralf Lange, MD, Alice Fabarius, PhD, Mathias Hänel, MD, Frank Stegelmann, MD, Jiri Mayer, MD, Arthur Gil, MPH, Danny Himsel, MSc, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Thomas Ernst, MD, Christian Fabisch, Dr.rer.MDc., Markus Pfirrmann, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 495.
https://doi.org/10.1182/blood-2019-130043
Published: 2019